PITTSBURGH, Oct. 2 /CNW/ -- Mylan Inc. (NYSE: MYL) announced today the
management transition plan at Dey L.P., Mylan's specialty pharmaceutical
business. As part of Merck Generics' integration into Mylan, Carolyn Myers,
Ph.D. has been appointed President-Elect of Dey and Christy Taylor has been
promoted to Chief Operating Officer, Dey.
Dr. Myers currently serves as President of Mylan Technologies, a position
she has held since February 2006. While at Mylan Technologies, Dr. Myers has
overseen the design, development and manufacture of Mylan's transdermal drug
delivery system. She first joined Mylan in 2003 as Vice President of Branded
Business Development and Strategic Marketing. Prior to joining Mylan, Dr.
Myers served as Global Director Cardiovascular at Pharmacia Inc.
Ms. Taylor initially joined Dey in 2002, most recently serving as
Executive Vice President of sales, marketing, business development and
government affairs. In this role, she has directed marketing, Dey's three
sales teams, sales operations, as well as the business development activities
of the Company. In addition, Ms. Taylor has led the government affairs
efforts on behalf of Dey. Before joining Dey, Ms. Taylor was vice chairman of
Nelson Professional Sales, a provider of integrated selling solutions to the
Mylan's Vice Chairman and CEO Robert J. Coury commented: "Carolyn has
been a valuable addition to the Mylan team since joining us four years ago to
oversee our brand development strategy and, most recently, our extremely
successful transdermal business. Her strong leadership skills and balanced
background in science, marketing and business development make her ideally
suited to lead Mylan's specialty division."
Dr. Myers said: "I am pleased to be taking on this new position within
Mylan. Dey's industry-leading respiratory business will form the base of a
strong specialty division, which is highly complimentary to the new Mylan. I
look forward to working with Christy and the other members of Dey's senior
management team to take this already strong business to a new level."
Mr. Coury continued: "Christy is an outstanding individual and leader,
who has played a pivotal part in the development of Dey's business. Combining
Carolyn's background with Christy's general management expertise and intimate
knowledge of Dey will ensure that Mylan effectively and efficiently
capitalizes on the business opportunities in the global specialty
Ms. Taylor commented: "I am excited to be taking on this new expanded
role within Dey. Over the past few months, I have had the privilege to get to
know Carolyn and other members of the Mylan senior management team and am
excited by the fact that we share a similar culture, values, and a commitment
to creating a strong specialty business. "
As part of the management integration, Mel Engle, Dey's current President
and Chief Executive Officer, will step down. Mr. Engle will remain President
of Dey until December 31, 2007 at which point he will be formally succeeded by
Dr. Myers. Ms. Taylor's new position as Chief Operating Officer of Dey will
take effect immediately. During the transition, Dr. Myers will also continue
to oversee Mylan Technologies.
Dr. Myers received her Ph.D. from the University of British Columbia,
Canada, a post-doctorate degree from the University of Wisconsin and a
Master's in Business Administration from Rutgers University.
Ms. Taylor earned her Bachelor of Science in Business from St. Mary's
College, and her Master's in International Business from the American Graduate
School of International Management.
Mylan Inc. is one of the world's leading quality generic and specialty
pharmaceutical companies. The Company offers one of the industry's broadest
and highest quality product portfolios, a robust product pipeline and a global
commercial footprint through operations in more than 90 countries. Through
its controlling interest in Matrix Laboratories Limited, Mylan has direct
access to one of the largest active pharmaceutical ingredient (API)
manufacturers in the world. Dey L.P., Mylan's fully integrated specialty
business, provides the Company with innovative and diversified opportunities
in the respiratory and allergy therapeutic areas.
For more information about Mylan, please visit www.mylan.com.
For further information:
For further information: Kris King, Mylan Inc., +1-724-514-1800 Web